Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa

The Lancet Global Health

Volumn 2, Issue 10, 2014, Pages e554-e556

  Dheda, Keertan ^a   Theron, Grant ^a,b   Welte, Alex ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Institute of Infectious Disease and Molecular Medicine   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE DURATION; DISEASE TRANSMISSION; ECONOMIC ASPECT; GROSS NATIONAL PRODUCT; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LIFESPAN; LIGHT EMITTING DIODE; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; ORGANIZATION AND MANAGEMENT; SPUTUM SMEAR; TUBERCULOSIS; XPERT MTB RIF ASSAY; DEVICES; ECONOMICS; FLUORESCENCE MICROSCOPY; MICROBIOLOGY; SPUTUM;

HUMANS; MICROSCOPY, FLUORESCENCE; SPUTUM; TUBERCULOSIS;

EID: 84907279823     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70305-5     Document Type: Note

References (19)

1. Steingart KR, Sohn H, Schiller I, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014, 1.
2. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011, 184:132-140.
3. Cohen GM, Drain PK, Noubary F, Cloete C, Bassett IV Diagnostic delays and clinical decision-making with centralized Xpert MTB/RIF testing in Durban, South Africa. J Acquir Imm Defic Syndr 2014, Published online August 12. http://dx.doi.org/10.1097/QAI.0000000000000309.
4. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB / RIF system for the diagnosis of pulmonary and extrapulmonary tuberculosis in adults and children WHO, (accessed Sept 5, 2014). http://apps.who.int/iris/handle/10665/112472.
5. Scully T Tuberculosis. Nature 2013, 502:S1-SS.
6. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014, 383:424-435.
7. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infect Dis 2014, 14:527-532.
8. Theron G, Pooran A, Peter J, et al. Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?. Eur Respir J 2012, 40:161-168.
9. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J 2013, 42:708-720.
10. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011, 8:e1001120.
11. Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012, 9:e1001347.
12. Langley I, Lin H-H, Egwaga S, et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Health 2014, 2:e581-e591.
13. Getahun H, Harrington M, O'Brien R, Nunn P Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007, 369:2042-2049.
14. Lin H-H, Dowdy D, Dye C, Murray M, Cohen T The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ 2012, 90:739-747.
15. Swai HF, Mugusi FM, Mbwambo JK Sputum smear negative pulmonary tuberculosis: sensitivity and specificity of diagnostic algorithm. BMC Res Notes 2011, 4:475.
16. Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis 2013, 13:507.
17. Nakiyingi L, Bwanika JM, Kirenga B, et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult tuberculosis suspects in Uganda. PLOS One 2013, 8:e74023.
18. Huerga H, Varaine F, Okwaro E, et al. Performance of the 2007 WHO algorithm to diagnose smear-negative pulmonary tuberculosis in a HIV prevalent setting. PLoS One 2012, 7:e51336.
19. Barter D, Agboola S, Murray M, Barnighausen T Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa-a systematic review. BMC Public Health 2012, 12:980.